Date | Interest Coverage Ratio | Debt to Equity Ratio | Interest Expense To Sales | Inventory Turnover Ratio |
---|
CEO | Dr. Hans T. Schambye M.D., Ph.D. |
IPO Date | Oct. 29, 2020 |
Location | United States |
Headquarters | 75 State Street |
Employees | 13 |
Sector | Health Care |
Industries |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Past 5 years
USD 1.44
USD 5.56
USD 14.84
USD 3.00
USD 39.83
USD 46.50
USD 4.57
USD 27.52
USD 10.01
USD 1.56
USD 11.16
USD 5.56
USD 30.05
USD 3.13
StockViz Staff
January 15, 2025
Any question? Send us an email